These last studies allowed the Federal Drug Administration (FDA; 2019) to approve pembrolizumab in combination with platinum and fluorouracil, regardless of PD‐L1 status, for the treatment of recurrent and/or metastatic HNSCC, and for monotherapy in patients with CPS ≥ 1 evaluated with an FDA‐approved test.11 This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.